Adovate develops novel drugs that target adenosine receptors involved in major diseases. These drug candidates have been created using our next-generation adenosine drug development platform, which enable design of patented compounds with favorable physiochemical characteristics and distribution kinetics that historically limited drugs acting against the adenosine receptors.
Our adenosine platform is a cornerstone of our company and confers a competitive advantage that will allow us to broaden our future drug pipeline efficiently and economically
Adenosine and Adovate